Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

West Pharmaceutical Services Inc Narrows FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Raises Low End Of Prior FY 2013 EPS Guidance To A Range In Line With Analysts' Estimates


Thursday, 31 Oct 2013 07:00am EDT 

West Pharmaceutical Services Inc updated its fiscal 2013 guidance and expects consolidated net sales in the range of $1.360-$1.380 billion compared to prior range of $1.350-$1.390 billion, diluted earnings per share (EPS) in the range of $1.58-$1.63 compared to prior range of $1.56-$1.64 and adjusted diluted EPS of $1.58-$1.63 compared to prior range of $1.55-$1.63. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.366 billion and EPS of $1.60 for fiscal 2013. 

Company Quote

52.11
0.17 +0.33%
26 Nov 2014